Skip to content

CIK 0001621443

ZYNE Zynerba Pharmaceuticals, Inc.

Insider trading from SEC Form 4. Last filing Oct 11, 2023.

In brief

Zynerba Pharmaceuticals, Inc. (ZYNE) has 12 SEC Form 4 filings on file from 12 insiders, the latest filed on Oct 11, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Signals

Open-market buys and sells at Zynerba Pharmaceuticals, Inc., scored.

No scored open-market trades yet. Grants, exercises and other rows are below.

Transactions

Every row filed, 50 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Oct 10, 2023Kenneth T Jones
See Remarks
UTender of shares
Common Stock
-40,520--45,000Oct 11, 2023
Oct 10, 2023Pamela Stephenson
director
UTender of shares
Common Stock
-27,954--47,824Oct 11, 2023
Oct 10, 2023Brian Rosenberger
VP, Commercial & Business Dev.
UTender of shares
Common Stock
-69,559--180,000Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
UTender of shares
Common Stock
-566,722--370,000Oct 11, 2023
Oct 10, 2023Daniel L Kisner
director
UTender of shares
Common Stock
-27,954--47,824Oct 11, 2023
Oct 10, 2023James E Fickenscher
Chief Financial Officer
UTender of shares
Common Stock
-123,087--255,000Oct 11, 2023
Oct 10, 2023William J Federici
director
UTender of shares
Common Stock
-27,954--47,824Oct 11, 2023
Oct 10, 2023Albert P Parker
Chief Legal Officer
UTender of shares
Common Stock
-33,685--193,333Oct 11, 2023
Oct 10, 2023Terri B Sebree
President
UTender of shares
Common Stock
-341,241--255,000Oct 11, 2023
Oct 10, 2023Warren D Cooper
director
UTender of shares
Common Stock
-27,954--47,824Oct 11, 2023
Oct 10, 2023John P. Butler
director
UTender of shares
Common Stock
-32,941--47,824Oct 11, 2023
Oct 10, 2023Kenneth I Moch
director
UTender of shares
Common Stock
-27,954--47,824Oct 11, 2023
Oct 10, 2023John P. Butler
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Terri B Sebree
President
AGrant or award
Common Stock
+170,000--425,000Oct 11, 2023
Oct 10, 2023James E Fickenscher
Chief Financial Officer
AGrant or award
Common Stock
+170,000--425,000Oct 11, 2023
Oct 10, 2023Kenneth I Moch
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Warren D Cooper
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
AGrant or award
Common Stock
+240,000--610,000Oct 11, 2023
Oct 10, 2023Albert P Parker
Chief Legal Officer
AGrant or award
Common Stock
+85,000--278,333Oct 11, 2023
Oct 10, 2023Pamela Stephenson
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Brian Rosenberger
VP, Commercial & Business Dev.
AGrant or award
Common Stock
+120,000--300,000Oct 11, 2023
Oct 10, 2023William J Federici
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Kenneth T Jones
See Remarks
AGrant or award
Common Stock
+30,000--75,000Oct 11, 2023
Oct 10, 2023Daniel L Kisner
director
UTender of shares
Common Stock
-47,824--0Oct 11, 2023
Oct 10, 2023Kenneth I Moch
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023William J Federici
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023Albert P Parker
Chief Legal Officer
UTender of shares
Common Stock
-278,333--0Oct 11, 2023
Oct 10, 2023John P. Butler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023Brian Rosenberger
VP, Commercial & Business Dev.
UTender of shares
Common Stock
-300,000--0Oct 11, 2023
Oct 10, 2023James E Fickenscher
Chief Financial Officer
UTender of shares
Common Stock
-425,000--0Oct 11, 2023
Oct 10, 2023Terri B Sebree
President
UTender of shares
Common Stock
-425,000--0Oct 11, 2023
Oct 10, 2023Pamela Stephenson
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023Kenneth T Jones
See Remarks
UTender of shares
Common Stock
-75,000--0Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
UTender of shares
Common Stock
-610,000--0Oct 11, 2023
Oct 10, 2023Warren D Cooper
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023Daniel L Kisner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-34,663--0Oct 11, 2023
Oct 10, 2023Kenneth I Moch
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
UTender of shares
Common Stockindirect: See footnote
-26,595--0Oct 11, 2023
Oct 10, 2023William J Federici
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Albert P Parker
Chief Legal Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-200,000--0Oct 11, 2023
Oct 10, 2023John P. Butler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Brian Rosenberger
VP, Commercial & Business Dev.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-90,000--0Oct 11, 2023
Oct 10, 2023James E Fickenscher
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-125,000--0Oct 11, 2023
Oct 10, 2023Terri B Sebree
President
DDisposition to issuer
Stock Option (Right to Buy)derivative
-125,000--0Oct 11, 2023
Oct 10, 2023Pamela Stephenson
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Kenneth T Jones
See Remarks
DDisposition to issuer
Stock Option (Right to Buy)derivative
-21,250--0Oct 11, 2023
Oct 10, 2023Warren D Cooper
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Daniel L Kisner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-71,736--0Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
UTender of shares
Common Stockindirect: See footnote
-13,297--0Oct 11, 2023
Oct 10, 2023Armando Anido
Chairman & Chief Exec. Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-190,000--0Oct 11, 2023

Insiders

Everyone who has filed a Form 4 here.

Questions about ZYNE

Answered from the filings on this page, as of the latest one.

Are insiders buying ZYNE?

No. In the last 90 days no insider at Zynerba Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade ZYNE on the open market?

No open-market trade has been scored at Zynerba Pharmaceuticals, Inc.. The latest Form 4 on file was filed on Oct 11, 2023 and holds grants, exercises or other rows that are not market trades.

How many insiders file Form 4 at Zynerba Pharmaceuticals, Inc.?

12 people have filed a Form 4 at Zynerba Pharmaceuticals, Inc., among them Armando Anido (Chairman & Chief Exec. Officer), John P. Butler (CEO, president and director), Warren D Cooper (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

ZYNE insider trading: Zynerba Pharmaceuticals, Inc. | InsiderTell